HWM
STRO icon

HighMark Wealth Management’s Sutro Biopharma STRO Stock Holding History

HighMark Wealth Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$572 Hold
23
– – ﹤0.01% 507
2025
Q4 		$266 Hold
23
– – ﹤0.01% 558
2025
Q3 		$195 Hold
23
– – ﹤0.01% 583
2025
Q2 		$161 Hold
23
– – ﹤0.01% 593
2025
Q1 		$146 Sell
23
-202
-90% -$3.18K ﹤0.01% 556
2024
Q4 		$4.14K Hold
225
– – ﹤0.01% 395
2024
Q3 		$7.79K Hold
225
– – ﹤0.01% 331
2024
Q2 		$6.59K Hold
225
– – ﹤0.01% 349
2024
Q1 		$12.7K Hold
225
– – 0.01% 244
2023
Q4 		$9.65K Hold
225
– – 0.01% 267
2023
Q3 		$7.81K Sell
225
-33
-13% -$1.44K 0.01% 288
2023
Q2 		$12K Hold
258
– – 0.01% 240
2023
Q1 		$11.9K Sell
258
-10
-4% -$635 0.01% 273
2022
Q4 		$21.6K Sell
268
-130
-33% -$9.04K 0.02% 164
2022
Q3 		$22K Sell
398
-60
-13% -$3.55K 0.02% 153
2022
Q2 		$24K Hold
458
– – 0.02% 145
2022
Q1 		$38K Hold
458
– – 0.03% 125
2021
Q4 		$68K Sell
458
-103
-18% -$18.5K 0.04% 99
2021
Q3 		$106K Buy
561
+14
+3% +$2.66K 0.08% 75
2021
Q2 		$102K Buy
547
+418
+324% +$81.8K 0.08% 75
2021
Q1 		$29K Buy
129
+60
+87% +$14.2K 0.02% 144
2020
Q4 		$15K Buy
+69
New +$11.4K 0.01% 184

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HighMark Wealth Management's STRO Position: Q1 2026 in Review

HighMark Wealth Management held its Sutro Biopharma (STRO) position steady in Q1 2026 at 23 shares worth $572. The position accounts for ﹤0.01% of the portfolio, ranked #507.

HighMark Wealth Management first reported a position in STRO in Q4 2020 and has held it in 22 quarters since. The position peaked at $106K in Q3 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • HighMark Wealth Management held 23 shares of Sutro Biopharma worth $572 as of Q1 2026.
  • HighMark Wealth Management left its Sutro Biopharma share count unchanged in Q1 2026.
  • Sutro Biopharma made up ﹤0.01% of HighMark Wealth Management's portfolio in Q1 2026, its #507 holding.
  • HighMark Wealth Management first reported a position in Sutro Biopharma in Q4 2020 and has held it in 22 quarters since.
  • HighMark Wealth Management's Sutro Biopharma position peaked at $106K in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.